Lundbeck CEO talks drug pricing, protecting biotech and European needsnews2026-03-10T18:28:19+00:00March 10th, 2026|Endpoints News|
FDA widens use of leucovorin without new trial datanews2026-03-10T13:00:12+00:00March 10th, 2026|Endpoints News|
Ipsen pulls cancer drug Tazverik from market over safety risksnews2026-03-09T18:16:40+00:00March 9th, 2026|Endpoints News|
Hims agrees to limit compounding, ending feud with Novo Nordisknews2026-03-09T14:44:20+00:00March 9th, 2026|Endpoints News|
Incyte receives CRL over issues at Novo’s Indiana factorynews2026-03-09T13:21:57+00:00March 9th, 2026|Endpoints News|
Lonza sells capsule and health ingredients unit for $2.2Bnews2026-03-06T19:50:51+00:00March 6th, 2026|Endpoints News|
Servier to buy Day One for $2.5B, gaining rare oncology medicinesnews2026-03-06T15:54:59+00:00March 6th, 2026|Endpoints News|
Pfizer gets obesity drug approval in China shortly after buying local rightsnews2026-03-06T12:29:57+00:00March 6th, 2026|Endpoints News|
Kura says its menin inhibitor is preferred treatment for some payersnews2026-03-05T20:34:01+00:00March 5th, 2026|Endpoints News|
Roche partner Zealand posts Phase 2 data for amylin obesity drugnews2026-03-05T20:19:31+00:00March 5th, 2026|Endpoints News|
